Perspectives for the Use of Bacterial Lysates for the Treatment of Allergic Rhinitis: A Systematic Review
Kamil Janeczek,Agnieszka Kaczyńska,Andrzej Emeryk,Cemal Cingi
DOI: https://doi.org/10.2147/JAA.S360828
2022-06-24
Journal of Asthma and Allergy
Abstract:Kamil Janeczek, 1 Agnieszka Kaczy&nacuteska, 1 Andrzej Emeryk, 1 Cemal Cingi 2 1 Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin, Lublin, Poland; 2 Department of Otorhinolaryngology, Faculty of Medicine, Eski&scedilehir Osmangazi University, Eski&scedilehir, Turkey Correspondence: Kamil Janeczek, Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin, Prof. A. G&eogonbali 6, Lublin, 20-093, Poland, Tel +48817185477, Email Bacterial lysates (BLs) are mixtures of bacterial antigens that have been used for many decades to minimize the risk of recurrent respiratory tract infections in both pediatric and adult populations. Research on the use of BLs is also conducted in allergology. Biomedical databases were searched for articles on the use of BLs in the treatment of allergic rhinitis (AR). After rejecting ineligible articles, six remaining reports were reviewed. Based on this review, it can be concluded that adding BL to standard therapy for seasonal or perennial AR reduces the severity of nasal symptoms and the need for antiallergic medications in both children and adults. Concurrently, these formulations have a high safety profile. An analysis of studies shows that the first effects of BLs therapy appear at the earliest 2– 6 weeks after the start of treatment and persist at least 3 months after treatment. Keywords: bacterial lysate, allergic rhinitis, immunostimulation, treatment Allergic rhinitis (AR) is a widely prevalent condition of the upper respiratory tract. It affects about 10% to 40% of the population worldwide (10–30% in adults and up to 40% in children). 1–3 The prevalence of the disease in some countries is continuously increasing, possibly due to lifestyle changes and increased urbanization. The described tendency is associated not only with AR but also with other atopic diseases, such as asthma and atopic dermatitis. 4 AR is characterized by rhinorrhoea, blocked nose, sneezing and itchy nose. In most cases also ocular symptoms are observed. 2,5 Described manifestations affect a patient's quality of life by sleep disturbance, which could be a risk factor of sleep-disordered breathing, learning disabilities and changes in a child's behaviour. 6 AR can also lead to sinus infections, otitis, development or exacerbations of asthma. 7 Multiple complications of the disease and a substantial impact on the patient's quality of life make it essential to conduct effective treatment devoid of side effects. According to the current guidelines, intranasal corticosteroids, intranasal and oral H1-antihistamines, anticholinergic, antileukotriene, alpha-mimetic agents and cromones are used. 8 However, the effectiveness of these medications may be limited, and most of them are burdened with side effects, which create a need to find new treatment methods. Based on the available literature, it appears that bacterial lysates (BLs) may be one of the therapeutic options for patients with allergic diseases. BLs are antigen mixtures obtained from inactivated pathogenic respiratory bacteria. They can be divided into two groups, based on the methods that are used to prepare the mixture: polyvalent mechanical bacterial lysates (PMBLs) and polyvalent chemical bacterial lysates (PCBLs). 9 BLs have been used since the 1950s to minimize the risk of recurrent respiratory tract infections in both pediatric and adult populations. Moreover, they have been proven to shorten the duration of respiratory infections and reduce the frequency of antibiotic therapy. 10–12 In the past decades, different studies investigating BLs have shown also their beneficial effect in prevention and therapy of atopic dermatitis in children, 13,14 seasonal and perennial AR therapy in children and adults 15–20 and preschool wheezing and childhood asthma therapy. 21,22 In this review, our purpose is to analyse the trial results and describe new ideas for bacterial lysate treatment in patients with AR. In August 2021, the authors searched biomedical databases (PubMed, Web of Science, Scopus, Cochrane Library) for articles about the usage of BLs in the treatment of AR. In all the databases, we used the following keywords: "allergic rhinitis", "bacterial lysate" and "bacterial extract". The search was performed by two independent persons (KJ, AE). All the relevant studies were identified by title and abstract reading. Duplicated articles were initially excluded. A careful analysis of full texts was done. Any disagreements were resolved by discussion. The search strategies are shown in Figure 1. Figure 1 The search strategies. Studies to be included in this descriptive review had -Abstract Truncated-
immunology,allergy,respiratory system